

## Agenda

### THURSDAY, JANUARY 27

- 3:00-3:05pm Welcome and introduction: **Francine M. Foss, Kensei Tobinai**  
 3:05-3:10 Introduction of keynote presenter: **Kensei Tobinai**  
 3:10-3:45 Keynote address: The definitive, final classification system for T-cell lymphomas: **James Armitage**

#### SESSION 1 Classification, epidemiology, and prognosis

**Moderators: James O. Armitage; Elaine S. Jaffe**

- 3:50-4:10 Classifying T-cell lymphomas—proposed functional-based systems: **Daniel M. Jones**  
 4:10-4:30 Prevalence of different T-cell lymphoma subtypes by geographic region: **Julie M. Vose**  
 4:30-4:50 Blastic NK-cell lymphoma & precursor NK-cell malignancy: **Ritsuro Suzuki**  
 4:50-5:10 Prognostic models in T-cell lymphomas: **Andrea Gallamini**  
 5:10-5:30 New gene expression markers for prognosis: **Randy D. Gascoyne**  
 5:30-5:50 Using miRNA as prognostic markers: **Miguel A. Piris**  
 5:50-6:05 **Poster presentation**  
 6:05-6:10 Day 1 closing remarks: **Francine M. Foss**  
 6:10-10:00 **Welcome dinner/reception**

### FRIDAY, JANUARY 28

- 7:00-8:00am Breakfast  
 8:00-8:05 Opening remarks: **Kensei Tobinai**

#### SESSION 2 Rare and T-cell lymphomas of unspecified origin

**Moderators: Kensei Tobinai; Madeleine Duvic**

- 8:05-8:25 GELA data on rare T-cell lymphomas: **Christian Gisselbrecht**  
 8:25-8:45 T-cell PLL: **Mitchell S. Cairo**  
 8:45-9:05 Gamma-delta T-cell lymphomas: **Elaine S. Jaffe**  
 9:05-9:25 Aggressive NK-cell leukemia: **Fumihiko Ishida**  
 9:25-9:45 Celiac disease and enteropathy-associated T-cell lymphoma: **Anne Lennard**  
 9:45-10:05 Hepatosplenic T-cell lymphoma: **Wyndham H. Wilson**  
 10:05-10:20 **BREAK**  
 10:20-10:40 NK-cell lymphoma of the infrequently involved sites: **Won Seog Kim**  
 10:40-11:00 Malignancies vs nonmalignancies: T-cell lymphoproliferative disease: **Joan Guitart**  
 11:00-11:20 Cytotoxic T-cell Lymphoma Working Group: **Shigeo Nakamura**  
 11:20-11:40 EBV-associated T-cell lymphoma and cofactors involved in EBV transformation: **Hiroshi Kimura**  
 11:40-12:00pm **Poster presentation**  
 12:00-1:00 **LUNCH**

#### SESSION 3 CD30-positive T-cell lymphomas

**Moderators: Susan Bates; Yok-Lam Kwong**

- 1:00-1:20 CD30-positive diseases of the skin: **Lauren C. Pinter-Brown**  
 1:20-1:40 CD30-positive systemic lymphomas: **Steven T. Rosen**  
 1:40-2:00 Treating CD30-positive lymphoma: ALK inhibitors: **Stephan W. Morris**  
 2:00-2:20 Treating CD30-positive lymphoma: Anti-CD30 monoclonal antibodies: **Ranjana Advani**  
 2:20-2:35 **Poster presentation**  
 2:35-2:45 **BREAK**

**SESSION 4** New treatment strategies for T-cell lymphomas**Moderators:** Wyndham H. Wilson; Lauren C. Pinter-Brown

- 2:45-3:05 Current treatment algorithms in the West: **Francine M. Foss**  
 3:05-3:25 Current treatment algorithms in the East: **Yok-Lam Kwong**  
 3:25-3:45 Treatment strategies for adult T-cell leukemia-lymphoma: **Kensei Tobinai**  
 3:45-4:05 The role of PET/CT in evaluating patients: **Bruce D. Cheson**  
 4:05-4:25 Radiation therapy for nasal NK/T-cell lymphoma: **Masahiko Oguchi**  
 4:25-4:45 Targeting the microenvironment in AITL: **Philippe Gaulard**  
 4:45-5:05 Immunology and antibody therapy: Targeting chemokine receptors: **Ryuzo Ueda**  
 5:05-5:25 Using genomics to identify new therapeutic targets: **Megan Lim**  
 5:25-5:40 **Poster presentation**  
 5:40-5:45 Day 2 closing remarks: **Francine M. Foss**

**SATURDAY, JANUARY 29**

- 7:00-8:00am Breakfast  
 8:00-8:05 Opening remarks: **Francine M. Foss**

**SESSION 5** New agents and rational combinations in T-cell lymphomas**Moderators:** Francine M. Foss; Steven T. Rosen

- 8:05-8:25 Chemotherapy combinations: Improving on CHOP: **Francesco A. d'Amore**  
 8:25-8:45 Kinase inhibitors: tyrosine and cell-cycle kinases (MP470, enzastaurin, Aurora kinase A): **Wei-Li Zhao**  
 8:45-9:05 HDAC inhibitors: Panobinostat, belinostat, romidepsin, vorinostat: **Susan E. Bates**  
 9:05-9:25 Folate analogs: **Steve M. Horwitz**  
 9:25-9:45 Monoclonal antibodies: **Claire E. Dearden**  
 9:45-10:05 L-asparaginase-containing chemotherapy for NK/T-cell lymphoma: **Motoko Yamaguchi**  
 10:05-10:25 Nucleoside analogs: **Madeleine Duvic**  
 10:25-10:45 Proteasome inhibitor bortezomib: **Pier Luigi Zinzani**  
 10:45-11:05 mTOR inhibitors: **Barbara Pro**  
 11:05-11:25 Skin-directed treatments for CTCL: **Youn Kim**  
 11:25-11:40 **Poster presentation**  
 11:40-11:50 **Break**

**SESSION 6** Transplantation**Moderators:** Pier Luigi Zinzani, Kensei Tobinai

- 11:50-12:10pm Autologous vs allogeneic transplant: Japanese and Korean Cooperative Study update: **Sung-Won Kim**  
 12:10-12:30 Reduced-intensity regimens before allogeneic treatment in relapsed PTCL: **Francine M. Foss**  
 12:30-12:50 Selecting patients for autologous transplant: who and how to pick: **Andrei Shustov**  
 12:50-1:00 **Poster presentation**  
 1:00-1:05 **Summary and adjournment**  
**Lunch and departures**